MAHA-era Shifts Narrow Accelerated Approvals and Affect Biotech Investment

Under MAHA-era FDA leadership, the agency has tightened the accelerated approval pathway, and accelerated approvals fell from 20 in 2024 to nine in 2025, the article reports.

Under current MAHA-era FDA leadership, officials have publicly pushed for greater regulatory flexibility while recent agency actions have tightened standards for accelerated approvals. That tension is focused on rare-disease drug development, where small patient populations make large trials difficult. The agency has recently denied several high-profile accelerated approval requests and asked for larger or different studies. These shifts have coincided with visible market reactions and debate among scientists and investors. Key facts: - The article reports that FDA Commissioner Marty Makary has promoted regulatory flexibility and has cited high-profile personalized therapies as examples. - The article reports accelerated approvals declined from 20 in 2024 to nine in 2025, according to RBC Capital Markets. - The article mentions that Vinay Prasad, head of the FDA's Center for Biologics Evaluation and Research, has led a stricter review approach and that several companies, including uniQure, saw denials and related stock moves. - The article mentions other cases where regulatory decisions and later responses, including a White House intervention on a vaccine review, produced rapid market reversals. Summary: The reported tightening of the accelerated approval pathway has increased uncertainty for rare-disease developers and for investors who track regulatory risk. Undetermined at this time.